Association of Genetic Characteristics with Response to Venetoclax Plus Hypomethylating Agents in Relapsed and Refractory Acute Myeloid Leukemia

被引：2
|
作者：
Weng, Guangyang [1 ,2 ]
Zhang, Yu [1 ]
Yu, Guopan [1 ]
Xu, Na [1 ]
Sun, Zhiqiang [3 ]
Lin, Dongjun [4 ]
Liang, Xinquan [5 ]
Deng, Lan [6 ]
Xiao, Jie [7 ]
Zhang, Hongyu [8 ]
Guo, Ziwen [9 ]
Jin, Hua [1 ]
Du, Xin [10 ]
Liu, Qifa [1 ]
机构：
[1] Southern Med Univ, Nanfang Hosp, Dept Hematol, Guangzhou, Peoples R China
[2] Shenzhen Univ, Peoples Hosp Shenzhen 2, Affiliated Hosp 1, Dept Hematol, Shenzhen, Peoples R China
[3] Southern Med Univ, Shenzhen Hosp, Dept Hematol, Shenzhen, Peoples R China
[4] Sun Yat Sen Univ, Affiliated Hosp 7, Dept Hematol, Shenzhen, Peoples R China
[5] First Peoples Hosp Chenzhou, Dept Hematol, Chenzhou, Peoples R China
[6] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Dept Hematol, Shanghai, Peoples R China
[7] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Hematol, Guangzhou, Peoples R China
[8] Peking Univ, Dept Hematol, Shenzhen Hosp, Shenzhen, Peoples R China
[9] Zhongshan City Peoples Hosp, Dept Hematol, Zhongshan, Peoples R China
[10] Shenzhen Univ, Affiliated Hosp 1, Shenzhen Peoples Hosp 2, Dept Hematol, Shenzhen, Peoples R China
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-158762
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页码：2025 / 2026
页数：2
相关论文
共 50 条
  • [21] Outcomes of Adults Treated with a Hypomethylating Agent Plus Venetoclax for Relapsed/Refractory Acute Myeloid Leukemia: A Multicenter Retrospective Study
    Geramita, Emily
    Wang, Hong
    Bastacky, Melissa
    Cohen, Jessica
    Shallis, Rory Michael
    Badar, Talha
    Litzow, Mark R.
    Im, Annie
    BLOOD, 2022, 140 : 6187 - 6188
  • [22] Real-world results of venetoclax combined with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukemia
    Xu, Xuezhu
    Liu, Rui
    He, Aili
    Wang, Fangxia
    HEMATOLOGY, 2023, 28 (01)
  • [23] Venetoclax combination therapy with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukaemia
    Baez-Gutierrez, Nerea
    Rodriguez-Ramallo, Hector
    Antonia-Perez Moreno, Maria
    Arboli, Eduardo-Rodriguez
    Abdel-Kader Martin, Laila
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2021, 12
  • [24] Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens
    Maiti, Abhishek
    Rausch, Caitlin R.
    Cortes, Jorge E.
    Pemmaraju, Naveen
    Daver, Naval G.
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Borthakur, Gautam M.
    Naqvi, Kiran
    Ohanian, Maro
    Short, Nicholas J.
    Alvarado, Yesid
    Benton, Christopher B.
    Benton, Christopher B.
    Kadia, Tapan M.
    Takahashi, Koichi
    Yilmaz, Musa E.
    Jain, Nitin
    Kornblau, Steven M.
    Bravo, Guillermo Montalban
    Sasaki, Koji
    Andreeff, Michael
    Bose, Prithviraj
    Ferrajoli, Alessandra
    Issa, Ghayas C.
    Jabbour, Elias
    Masarova, Lucia
    Rytting, Michael E.
    Thompson, Philip A.
    Wang, Sa A.
    Konoplev, Sergej
    Chen, Zhining
    Goswami, Maitrayee
    Maduike, Rita
    Guerrero, Julio A.
    Zhang, Qi
    Cavazos, Antonio
    Ma, Helen
    Bivins, Carol A.
    Wade, Allison
    Adewale, Shadiat L.
    Tse, Susan
    Thomas, Robin
    Vaughan, Kenneth
    Pierce, Sherry A.
    Ning, Jing
    Qiao, Wei
    Welch, John S.
    Kantarjian, Hagop M.
    Konopleva, Marina Y.
    BLOOD, 2019, 134
  • [25] Response to Venetoclax and Hypomethylating Agents Among Prognostic Risk Groups and Genetic Subtypes of Acute Myeloid Leukemia
    Aldoss, Ibrahim
    Yang, Dongyun
    Pillai, Raju
    Sanchez, James F.
    Aribi, Ahmed
    Ali, Haris
    Sandhu, Karamjeet S.
    Al Malki, Monzr
    Mei, Matthew
    Salhotra, Amandeep
    Khaled, Samer K.
    Nakamura, Ryotaro
    Sun, Weili
    O'Donnell, Margaret R.
    Snyder, David S.
    Stein, Anthony S.
    Forman, Stephen J.
    Marcucci, Guido
    Pullarkat, Vinod A.
    BLOOD, 2018, 132
  • [26] Hypomethylating Agents and Venetoclax for Acute Myeloid Leukemia Relapsed After Hematopoietic Stem Cell Transplant
    Ionescu, Filip
    David, Jerel C.
    Ravichandran, Apoorva
    Sallman, David A.
    Sweet, Kendra
    Komrokji, Rami S.
    Chan, Onyee
    Kuykendall, Andrew
    Padron, Eric
    Faramand, Rawan
    Bejanyan, Nelli
    Khimani, Farhad
    Elmariah, Hany
    Pidala, Joseph
    Mishra, Asmita
    Perez, Lia
    Nishihori, Taiga
    Lancet, Jeffrey E.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (06): : 400 - 406
  • [27] Venetoclax with Hypomethylating Agents or Low-Dose Cytarabine for Relapsed/Refractory Acute Myeloid Leukemia in a Real-Life Setting
    Piccini, Matteo
    Pilerci, Sofia
    Scappini, Barbara
    Bencini, Sara
    Peruzzi, Benedetta
    Caporale, Roberto
    Signori, Leonardo
    Fabiana, Pancani
    Maria, Vannucchi Alessandro
    Gianfaldoni, Giacomo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S289 - S289
  • [28] A Successful Bridge Therapy Combining Hypomethylating Agents with Venetoclax for Adult Patients with Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia
    Bang, Su-Yeon
    Park, Silvia
    Kwag, Daehun
    Lee, Jong Hyuk
    Min, Gi-June
    Park, Sung-Soo
    Yoon, Jae-Ho
    Lee, Sung-Eun
    Cho, Byung-Sik
    Eom, Ki-Seong
    Kim, Yoo-Jin
    Lee, Seok
    Min, Chang-Ki
    Cho, Seok-Goo
    Lee, Jong Wook
    Kim, Hee-Je
    CANCERS, 2023, 15 (06)
  • [29] THE USE OF VENETOCLAX WITH HYPOMETHYLATING AGENTS (HMAS) FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA IN A REAL-LIFE SETTING: THE BOLOGNA EXPERIENCE
    Nanni, J.
    Cristiano, G.
    Marconi, G.
    Parisi, S.
    Sartor, C.
    Ottaviani, E.
    Baldini, L.
    Testoni, N.
    Baldazzi, C.
    Paolini, S.
    Cavo, M.
    Papayannidis, C.
    Curti, A.
    HAEMATOLOGICA, 2019, 104 : 137 - 137
  • [30] Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents—a multicenter historical prospective study
    Ron Ram
    Odelia Amit
    Tsila Zuckerman
    Ronit Gurion
    Pia Raanani
    Yael Bar-On
    Irit Avivi
    Ofir Wolach
    Annals of Hematology, 2019, 98 : 1927 - 1932
12345